Real-world clinical study of trastuzumab biosimilar (Zercepac) and pertuzumab (Perjeta) in combination with chemotherapy for neoadjuvant treatment of HER-2-positive breast cancer.

Yu-Fei Bao Jin-Zhe Yang Xiu-Feng Li Jing-Jun Zhu

Asian J Surg

Department of Breast Surgery, Baotou Cancer Hospital, Baotou, 014030, Inner Mongolia, China; Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, 014040, Inner Mongolia, China. Electronic address:

Published: July 2024

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.asjsur.2024.03.063	DOI Listing

Publication Analysis

Top Keywords

real-world clinical

clinical study

study trastuzumab

trastuzumab biosimilar

biosimilar zercepac

zercepac pertuzumab

pertuzumab perjeta

perjeta combination

combination chemotherapy

chemotherapy neoadjuvant

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!